Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development ...

Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces ...

Lentiviral vectors are derived from lentiviruses such as HIV-1 and serve as potent gene delivery vehicles due to their capacity to integrate stably into the host genome and transduce both dividing and ...

MADISON, Wis., Aug. 11, 2021 /PRNewswire/ -- Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion to the existing ...

Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced a poster presentation on ...

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk.